Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon completes its acquisition of PointR Data Inc.
Forms AI Driven Late Clinical-Stage Cancer Immunotherapy Company Focusing on TGF-β RNA Therapeutics in Rare Pediatric Diseases SANTA CLARA, Calif. and AGOURA HILLS, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN)  (‘Mateon”) announced today that they have completed
View HTML
Toggle Summary New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor
AGOURA HILLS, Calif. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, announced today the publication of a peer-reviewed research article authored by
View HTML
Toggle Summary FDA Grants Pediatric Disease Designation for Mateon’s OT101
For treatment of diffuse intrinsic pontine glioma (DIPG), a difficult to treat form of childhood brain tumor AGOURA HILLS, Calif. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration ( FDA ) granted Rare Pediatric
View HTML
Toggle Summary Mateon Partners With WideTrial for Data-Generating Expanded Access Programs in Cancer
AGOURA HILLS, Calif. and SAN FRANCISCO , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN), announced today that it has executed agreements with WideTrial Inc. for an Expanded Access program (EAP) in pancreatic cancer.  Using WideTrial’s novel platform, the investigational
View HTML
Toggle Summary Mateon Enters into Merger Agreement with PointR Data to Leverage Disruptive AI Technology in Its Innovation-Driven Quest for a Cure of Cancer
AGOURA HILLS, Calif. and SANTA CLARA, Calif. , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) and PointR Data Inc. (PointR), a privately-held, developer of high performance cluster computer and artificial intelligence company, announced today that they have
View HTML
Toggle Summary Oncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced Pivotal Phase 3 Clinical Testing
AGOURA HILLS, Calif. , July 30, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, announced today that its team members will participate and provide clinical
View HTML
Toggle Summary Internationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of Oncotelic
AGOURA HILLS, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic"), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to development of innovative treatments for cancer, announced today that Dr. John H. Sampson , an internationally recognized
View HTML
Toggle Summary Oncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory Board
AGOURA HILLS, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB: MATN) dedicated to development of innovative treatments for cancer announced today that four internationally recognized clinical scholars have joined
View HTML
Toggle Summary Mateon and Oncotelic Report on Continuing Integration of the two Businesses
-Relocation of Corporate Headquarters    -Introduction of Amit Shah as incoming CFO    -Presentation of Integrated Pipeline at BIO2019 AGOURA HILLS, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN), a biopharmaceutical company developing investigational drugs for
View HTML
Toggle Summary Mateon Reports First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 15, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, announced today financial results for the first quarter of 2019.
View HTML